You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19 stories in pics: 7 key updates that you may have missed this week

Here's a weekly round up of stories and updates related to coronavirus pandemic in brief

Coronavirus Tests | Coronavirus Vaccine

BS Web Team  |  New Delhi 

Remdesivir, HCQ have little or no effect

Remdesivir, HCQ have little or no effect
1 / 7

The World Health Organisation's (WHO) global clinical trial has found that the popular anti-viral drug remdesivir has no substantial impact on either mortality, initiation of ventilation or even duration of hospital stay. The results of the Solidarity Trial conducted on 11,266 hospitalised Covid-19 patients across 30 countries found that remdesivir along with other repurposed drug hydroxychloroquine (rheumatoid arthritis drug), lopinavir/ritonavir (used is leprosy) and interferon have little or no effect on overall mortality, initiation of ventilation and duration of hospital stay.

Five-minute rapid antigen test

Five-minute rapid coronavirus antigen test
2 / 7

Scientists from Britain’s University of Oxford have developed a rapid Covid-19 test able to identify the in less than five minutes, researchers said, adding it could be used in mass testing at airports and businesses.

Speedy recovery can add $9 trn to global income

Speedy recovery can add $9 trn to global income
3 / 7

Speeding up the recovery from the recession can add $9 trillion in global income by 2025, International Monetary Fund Managing Director Kristalina Georgieva said, adding that this depended on strong international cooperation, including on vaccines.


Vaccine in next few months in India

Vaccine in next few months in India
4 / 7

India is expected to have a Covid-19 vaccine in a few months and the country should be in the process of delivering it to people in the next six months, Union Health Minister Harsh Vardhan said. He said this potent social vaccine can stop the disease and it also forms the foundation of the 'Jan Andolan' against Covid-19.

Immunity may last for several months

Immunity may last for several months
5 / 7

Immunity against Covid-19 may persist for at least five months after being infected with the SARS-CoV-2 virus, according to a study led by an Indian-origin researcher in the US. The researchers from the University of Arizona studied the production of antibodies from a sample of nearly 6,000 people infected with the novel coronavirus.

IMF growth projection

IMF growth projection
6 / 7

The IMF has predicted a deep global recession this year and the world growth to be - 4.4 per cent, asserting that the global economic crisis is far from over mainly due to the impact of the coronavirus pandemic. In its latest World Economic Outlook report, the International Monetary Fund also said the swift recovery in China has surprised on the upside while the global economy's long ascent back to pre-pandemic levels of activity remains prone to setbacks.

Coronavirus can survive for 28 days on banknotes, mobile screens

Coronavirus can survive for 28 days on banknotes, mobile screens
7 / 7

A latest study has now found that the virus can survive for up to 28 days on common surfaces including banknotes and glass such as mobile phone screens and stainless steel. The study conducted by researchers at the Australian Centre for Disease Preparedness (ACDP) also found that the virus survived longer at lower temperatures and on non-porous or smooth surfaces compared to porous, complex surfaces such as cotton.

For more: Coronavirus can survive for 28 days on banknotes, mobile screens: Study

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 16 2020. 12:52 IST